Zacks Investment Research Upgrades Sientra Inc. (SIEN) to “Hold”
Sientra Inc. (NASDAQ:SIEN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Separately, William Blair reissued a “market perform” rating on shares of Sientra in a report on Wednesday, August 10th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $28.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zacks-investment-research-upgrades-sientra-inc-sien-to-hold.html
Sientra (NASDAQ:SIEN) opened at 8.40 on Wednesday. The company’s 50-day moving average is $7.98 and its 200 day moving average is $7.25. The company’s market cap is $152.33 million. Sientra has a 1-year low of $2.78 and a 1-year high of $20.63.
Sientra (NASDAQ:SIEN) last posted its earnings results on Tuesday, August 9th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.05. The company earned $6.20 million during the quarter, compared to the consensus estimate of $4.80 million. Sientra had a negative return on equity of 36.16% and a negative net margin of 297.09%. On average, equities analysts predict that Sientra will post ($2.31) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co purchased a new position in Sientra during the second quarter valued at about $198,000. Cannell Capital LLC increased its position in Sientra by 95.2% in the second quarter. Cannell Capital LLC now owns 855,997 shares of the company’s stock valued at $5,632,000 after buying an additional 417,364 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in Sientra during the second quarter valued at about $3,310,000. First New York Securities LLC NY increased its position in Sientra by 411.4% in the second quarter. First New York Securities LLC NY now owns 15,343 shares of the company’s stock valued at $101,000 after buying an additional 12,343 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Sientra by 67.5% in the first quarter. Geode Capital Management LLC now owns 71,919 shares of the company’s stock valued at $491,000 after buying an additional 28,980 shares in the last quarter. 68.85% of the stock is owned by institutional investors.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.